Annexon Reports $44.1 Million Net Loss in Q1 2026, Focuses on Clinical Programs

Annexon, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $44.1 million, a decrease from the $54.4 million loss recorded in the same period of 2025. The company's total operating expenses for the quarter were $46.1 million, down 20% from $57.4 million year-over-year. This reduction was primarily driven by a significant decrease in research and development expenses, which fell by 26% to $35.8 million, attributed to lower contract manufacturing costs and a reduction in personnel-related expenses.

The company's cash and cash equivalents, along with short-term investments, totaled $225 million as of March 31, 2026, compared to $238.3 million at the end of 2025. The decrease in total assets was accompanied by a reduction in total liabilities, which fell to $58.4 million from $65.9 million. The accumulated deficit increased to $961.5 million, reflecting the ongoing investment in research and development without any revenue from product sales, as the company has not yet received regulatory approvals for its product candidates.

Strategically, Annexon is advancing its late-stage clinical programs, including tanruprubart for Guillain-Barré Syndrome and vonaprument for geographic atrophy associated with age-related macular degeneration. The company has filed a Marketing Authorization Application for tanruprubart with the European Medicines Agency, which is currently under review. Additionally, the ongoing Phase 3 ARCHER II trial for vonaprument has completed enrollment, with topline data expected in late 2026.

Operationally, the company has seen a shift in its focus, with a notable increase in clinical and nonclinical outside services costs, which rose by 32% to $14 million, reflecting the ongoing trials for its product candidates. The total employee headcount has also adjusted, contributing to the decrease in personnel-related expenses. As of March 31, 2026, the company had 22.5 million stock options outstanding, an increase from the previous year, indicating ongoing efforts to attract and retain talent.

Looking ahead, Annexon anticipates continued losses as it invests in the development of its product candidates. The company projects that its existing cash and investments will support operations into the second half of 2027, but acknowledges the need for additional funding to sustain its research and development efforts. Future financing may come from equity offerings or collaborations, and the company is actively exploring these options to ensure the continuation of its clinical programs.